Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Datadog Inc (DDOG) Price & Performance

Amphastar Pharmaceuticals IncTrade
Datadog IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Datadog Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Datadog Inc trades at $246.61 (market cap $93.64B). The key difference: Datadog Inc is far larger — about 108.4× Amphastar Pharmaceuticals Inc's market cap, and Datadog Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AMPHDDOG
Market Cap
$863.95M$93.64B
Sector
HealthTechnology
52-Week High
$30.81$288.15
52-Week Low
$16.87$102.62
Enterprise Value
$1.26B$89.93B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Datadog Inc

Datadog (DDOG) trades at $233.93, up 2.02% today, but remains bearish technically with resistance near $244. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.65 versus $0.583 expected, and raised full-year revenue guidance to $4.45B-$4.47B. However, the stock faces pressure from high valuations, with a P/E of 467.86, and concerns over decelerating bookings growth from a major AI customer.

Outlook is mixed: robust revenue growth and AI momentum support long-term potential, but premium valuation and near-term usage volatility pose risks. Analyst consensus is bullish with an $288.55 price target, though insider selling and technical weakness suggest cautious near-term sentiment. Investors should balance growth prospects against execution risks and market expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG